Literature DB >> 10087029

Synergistic interactions between ampakines and antipsychotic drugs.

S A Johnson1, N T Luu, T A Herbst, R Knapp, D Lutz, A Arai, G A Rogers, G Lynch.   

Abstract

Tests were made for interactions between antipsychotic drugs and compounds that enhance synaptic currents mediated by alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid-type glutamate receptors ("ampakines"). Typical and atypical antipsychotic drugs decreased methamphetamine-induced hyperactivity in rats; the effects of near or even subthreshold doses of the antipsychotics were greatly enhanced by the ampakines. Interactions between the ampakine CX516 and low doses of different antipsychotics were generally additive and often synergistic. The ampakine did not exacerbate neuroleptic-induced catalepsy, indicating that the interaction between the different pharmacological classes was selective. These results suggest that positive modulators of cortical glutamatergic systems may be useful adjuncts in treating schizophrenia.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10087029

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  14 in total

Review 1.  Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment.

Authors:  Christine Konradi; Stephan Heckers
Journal:  Pharmacol Ther       Date:  2003-02       Impact factor: 12.310

2.  Differential effects of AMPA receptor potentiators and glycine reuptake inhibitors on antipsychotic efficacy and prefrontal glutamatergic transmission.

Authors:  Kent Jardemark; Monica M Marcus; Anna Malmerfelt; Mohammed Shahid; Torgny H Svensson
Journal:  Psychopharmacology (Berl)       Date:  2011-11-09       Impact factor: 4.530

Review 3.  Therapeutic potential of positive AMPA receptor modulators in the treatment of neuropsychiatric disorders.

Authors:  Stefano Marenco; Daniel R Weinberger
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 4.  Treatment of Parkinson's disease : what's on the horizon?

Authors:  Stacy S Wu; Steven J Frucht
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

5.  Translational PK-PD modelling of molecular target modulation for the AMPA receptor positive allosteric modulator Org 26576.

Authors:  Roberta Bursi; Gul Erdemli; Robert Campbell; Matthew M Hutmacher; Thomas Kerbusch; David Spanswick; Ross Jeggo; Kari R Nations; Peter Dogterom; Jacques Schipper; Mohammed Shahid
Journal:  Psychopharmacology (Berl)       Date:  2011-06-07       Impact factor: 4.530

Review 6.  N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives.

Authors:  Mark J Millan
Journal:  Psychopharmacology (Berl)       Date:  2005-03-10       Impact factor: 4.530

Review 7.  Pharmacology of AMPA/kainate receptor ligands and their therapeutic potential in neurological and psychiatric disorders.

Authors:  G J Lees
Journal:  Drugs       Date:  2000-01       Impact factor: 9.546

8.  Glutamatergic modulation of hyperactivity in mice lacking the dopamine transporter.

Authors:  R R Gainetdinov; A R Mohn; L M Bohn; M G Caron
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-25       Impact factor: 11.205

9.  A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia.

Authors:  Donald C Goff; J Steven Lamberti; Andrew C Leon; Michael F Green; Alexander L Miller; Jayendra Patel; Theo Manschreck; Oliver Freudenreich; Steven A Johnson
Journal:  Neuropsychopharmacology       Date:  2007-05-09       Impact factor: 7.853

Review 10.  Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia.

Authors:  Robert W Buchanan; Robert Freedman; Daniel C Javitt; Anissa Abi-Dargham; Jeffrey A Lieberman
Journal:  Schizophr Bull       Date:  2007-07-19       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.